Edition:
United States

Supernus Pharmaceuticals Inc (SUPN.OQ)

SUPN.OQ on NASDAQ Stock Exchange Global Market

26.10USD
17 Feb 2017
Change (% chg)

$-0.10 (-0.38%)
Prev Close
$26.20
Open
$26.15
Day's High
$26.45
Day's Low
$25.80
Volume
156,513
Avg. Vol
177,158
52-wk High
$27.90
52-wk Low
$12.16

SUPN.OQ

Chart for SUPN.OQ

About

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi... (more)

Overall

Beta: 1.84
Market Cap(Mil.): $1,308.16
Shares Outstanding(Mil.): 50.12
Dividend: --
Yield (%): --

Financials

  SUPN.OQ Industry Sector
P/E (TTM): 16.17 28.47 29.39
EPS (TTM): 1.61 -- --
ROI: 49.79 13.57 13.06
ROE: 66.48 14.45 14.19

BRIEF-Supernus announces issuance of eighth U.S. patent protecting Trokendi XR

* Supernus announces issuance of eighth U.S. Patent protecting Trokendi XR

Feb 08 2017

BRIEF-Supernus wins seventh patent for epilepsy drug Trokendi

* Supernus announces issuance of seventh u.s. Patent protecting Trokendi XR Source text for Eikon: Further company coverage:

Jan 30 2017

BRIEF-Supernus provides business update

* Supernus Pharmaceuticals Inc - net product sales for Q3 of 2016 were $55.6 million, a 44.1% increase over $38.6 million in same period last year

Nov 14 2016

BRIEF-Supernus Pharmaceuticals sees 2016 net product sales in range of $205 mln to $210 mln

* Sees 2016 net product sales in range of $205 million to $210 million

Nov 14 2016

BRIEF-Supernus Pharmaceuticals files for non-timely 10-Q

* Additional time needed to solve issue concerning accounting treatment of $30 million royalty monetization deal recorded as revenue in July 2014

Nov 10 2016

BRIEF-Supernus Pharmaceuticals reports positive results from Phase IIB clinical trial for SPN-812

* Supernus announces positive results from Phase IIB clinical trial for SPN-812 in children with ADHD

Oct 11 2016

More From Around the Web

Competitors

  Price Chg
Abbott Laboratories (ABT.N) $44.69 +0.49
AstraZeneca plc (AZN.L) 4,570.00 -25.00
Eli Lilly and Co (LLY.N) $80.39 +0.35
Shire PLC (SHP.L) 4,801.00 -35.00
Shire PLC (3159084.L) -- --
Smiths Group plc (SMIN.L) 1,515.00 +1.00

Earnings vs. Estimates